| Literature DB >> 19383165 |
Kristopher J Stanya1, Hung-Ying Kao.
Abstract
Corepressors are large proteins that facilitate transcriptional repression through recruitment of histone-modifying enzymes. Two major corepressors, SMRT (silencing mediator for retinoid and thyroid hormone receptors) and N-CoR (nuclear receptor corepressor), have been shown to mediate repression associated with nuclear receptors and a myriad of other transcription factors. This review will focus on recent studies on these proteins, including newly discovered physiological roles of the corepressors, their modes of regulation, their roles in antiestrogen-resistant breast cancer and their functions during the cell cycle.Entities:
Year: 2009 PMID: 19383165 PMCID: PMC2678994 DOI: 10.1186/1747-1028-4-7
Source DB: PubMed Journal: Cell Div ISSN: 1747-1028 Impact factor: 5.130
Figure 1Degradation of pathways for SMRT and N-CoR. SMRT and N-CoR are subject to unique degradation pathways. Estrogen (E2) increases mRNA levels of the E3 ubiquitin ligase mSiah2. mSiah2 targets N-CoR for degradation by the proteasome. SMRT is degraded by a distinct pathway. SMRT is phosphorylated by Cyclin-dependent kinase 2 (Cdk2) and potentially other kinases. Phosphorylated SMRT then serves as a substrate for the peptidyl-prolyl isomerase Pin1 which alters the conformation of its substrate. Both Pin1 levels and Cdk activity are increased by the oncoprotein ErbB2; furthermore, Pin1 can increase ErbB2 activity. SMRT is then degraded, likely by subsequent ubiquitination and targeting to the proteasome. Loss of corepressors likely increases transcription of target genes, including some involved in proliferation. Corepressor degradation also likely contributes to tamoxifen resistance.
Figure 2Corepressors and tamoxifen-resistant breastcancers. Estrogen receptors (ER) can interact with either coactivators or corepressors. Tamoxifen, a common treatment for ERα-positive breast cancers, induces an ERα conformational change that favors recruitment of corepressors to repress proliferative genes controlled by ERα. However, some breast cancers show ERα recruitment of coactivators even in the presence of tamoxifen, thus resulting in activation of proliferative genes. Many of these tamoxifen-resistant breast cancers overexpress the oncogene ErbB2, which has been shown to increase coactivator levels and decrease corepressor levels, thus altering the delicate ratio between these critical factors.